SS-31

SS-31, known generically as elamipretide, is a synthetic tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2. It belongs to the Szeto-Schiller (SS) family of mitochondria-targeting peptides developed by Hazel Szeto and Peter Schiller. The compound was designed with a specific architectural purpose: to selectively accumulate in the inner mitochondrial membrane by binding to cardiolipin ^[2], a unique phospholipid found almost exclusively in that membrane. No other cellular membrane contains cardiolipin in significant quantities, making it an exquisitely specific molecular address for targeted drug delivery to mitochondria without requiring a conventional targeting signal sequence.

The selectivity of SS-31 for the inner mitochondrial membrane is achieved through an alternating sequence of basic amino acid residues (D-Arg, Lys) and aromatic residues (dimethylTyr, Phe). The basic residues drive membrane association through electrostatic interactions, while the aromatic residues provide additional binding affinity through pi-electron interactions with the lipid bilayer. Importantly, despite bearing a net positive charge, SS-31 maintains excellent cell permeability, which research suggests is due to charge shielding by the electron-rich aromatic ring systems. This combination of membrane permeability and mitochondrial selectivity is unusual among pharmacological agents.

Once bound to cardiolipin at the inner mitochondrial membrane, SS-31 stabilizes the cardiolipin-cytochrome c interaction ^[2]. Cytochrome c is a key electron carrier in the mitochondrial electron transport chain (ETC); when cardiolipin is oxidized or peroxidized (as occurs during oxidative stress and aging), cytochrome c shifts from its electron carrier role to a peroxidase activity that generates damaging reactive oxygen species (ROS). SS-31 binding prevents this peroxidase shift, protecting the ETC from self-inflicted oxidative damage. The downstream effects include normalized electron transport chain efficiency, reduced mitochondrial ROS production, improved ATP synthesis, reduced mitochondrial membrane potential dysregulation, and protection against mitochondria-initiated apoptosis. Research published in PNAS identified that SS-31's interacting proteins cluster specifically around ATP synthase and the 2-oxoglutarate metabolic pathway.

Preclinical studies using SS-31 have produced compelling results across multiple disease models. Eight weeks of SS-31 treatment at 3 mg/kg/day in aged mice substantially reversed cardiac diastolic dysfunction, normalized proton leak, and reduced mitochondrial ROS production in heart muscle cells. In skeletal muscle, prolonged SS-31 treatment reversed age-related energetic deficits, improved resting and dynamic muscle function, and restored redox homeostasis. Kidney disease models (including ischemia-reperfusion injury) showed significant protection. SS-31 (as elamipretide) has entered human clinical trials under the pharmaceutical company Stealth BioTherapeutics, including trials in Barth syndrome (a rare mitochondrial cardiomyopathy) and heart failure with preserved ejection fraction (HFpEF), reflecting its therapeutic potential in mitochondrial dysfunction.